|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
Conference date: April 25, 2013 @ 5:00 AM Pacific Time
Biogen Idec: Too High Too Fast? [April 29, 2013]
Gilead Sciences, Biogen Idec, and Celgene [August 13, 2012]
Biogen Idec: Q3 Clues to Value [November 2, 2011]
Biogen Idec: Is there More Value? [July 11, 2011]
2013 |
|||
 |
|||
04/25/2013 |
|||
Q1 |
|||
2012 |
|||
|
|
|
|
05/01/2012 |
07/24/2012 |
10/25/2012 |
01/28/2013 |
Q1 |
Q2 |
Q3 |
Q4 |
2011 |
|||
|
|
|
|
04/21/2011 |
07/26/2011 |
10/28/2011 |
01/31/2012 |
Q1 |
Q2 |
Q3 |
Q4 |
2010 |
|||
|
|
|
|
04/20/2010 |
07/20/2010 |
10/26/2010 |
02/01/2011 |
Q1 |
Q2 |
Q3 |
Q4 |
2009 |
|||
|
|
|
|
04/16/2009 |
07/16/2009 |
10/20/2009 |
02/09/2010 |
Q1 |
Q2 |
Q3 |
Q4 |
2008 |
|||
|
|
|
|
04/23/2008 |
07/22/2008 |
10/21/2008 |
02/06/2009 |
Q1 |
Q2 |
Q3 |
Q4 |
2007 |
|||
|
|
|
|
02/06/2008 |
10/23/2007 |
07/24/2007 |
05/02/2007 |
Q4 |
Q3 |
Q2 |
Q1 |
2006 |
|||
|
|
|
|
02/15/2007 |
10/31/2006 |
07/26/2006 |
04/26/2006 |
Q4 |
Q3 |
Q2 |
Q1 |
Biogen Idec PML Test Approved in Europe, Changing Tysabri Outlook [March 15, 2011]
Biogen Idec Hemophilia Therapies [September 30, 2010]
Gilenya, Biogen Idec, and MS [September 22, 2010]
FDA February 5, 2010 Tysabri and PML letter
Biogen Research and Development Presentation notes [March 25, 2009]
Biogen Idec Growth Acceleration [October 27, 2008 blog]
Biogen Idec: Will it Recover? [September 1, 2008 blog]
Choosing a Biotech Stock 3: Biogen Idec [September 14, 2007 blog]
Rituxan and Zevalin, A Cautionary Tale [July 14, 2007 at New York Times, registration required]
Biogen Idec and Tysabri [May 6, 2007 blog]
First acquired in February 2008
Biogen Idec is a biotechnology pharmaceutical company which markets Rituxan, Zevalin, Avonex, Fumaderm, and Tysabri.
Biogen Idec Web site:
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. Before making or terminating an investment you should always verify any factual basis of your decision.